Equity Profile

ARGX

argenx SE

Health CareBiotechnology$54.5B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

argenx SE is a biotechnology company focused on developing therapies for severe autoimmune diseases and cancer. With a market cap of $54 billion, it plays a significant role in the health care sector, particularly in the innovative treatment landscape.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Expected to be around $5.52.

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1-2026, argenx reported an EPS of $5.52, surpassing estimates by 6.94%. However, the stock price fell by 2.51% the following day, indicating mixed market reactions.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to expanding the pipeline of therapies.
Plans to enhance partnerships with other biotech firms.

Expectations

Wall Street Expectations

Overall, expectations for argenx are cautiously optimistic, given their consistent EPS surprises in the past. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If argenx continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if the EPS falls short of expectations, it could lead to a significant sell-off.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.52.

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

Market Reaction

N/A

Understanding how the stock reacts post-earnings can provide insights into investor sentiment and future expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be critical in shaping investor sentiment.

Will there be any guidance on revenue growth?

Lack of revenue guidance has historically led to uncertainty, and any clarity on this front could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate argenx's ability to maintain its EPS surprise streak, given the strong pipeline and recent advancements.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

Recent clinical trial results may not yet be fully factored into current estimates.

Key Risk

If the EPS comes in below $5.30, it could challenge the current positive sentiment and lead to a reevaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching the EPS and any revenue guidance, as these will be key indicators of the company's ongoing performance and future outlook.

Bull Confirmed If

An EPS of $5.75 or higher would confirm strong operational performance and likely boost investor confidence.

Bear Confirmed If

An EPS below $5.30 would raise concerns about the company's growth trajectory and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±14.75%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations and raises guidance, history suggests the stock could rise by around 0.79% on the following day.

In-Line / Cautious

If results are in line with expectations but lack clear guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 5.01% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and outcomes.
2Management's commentary on revenue expectations and market conditions.
3Insights into partnerships or collaborations that may impact growth.
4Details on cost management and operational efficiencies.
5Future pipeline developments and their expected timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Expected to be around $5.52.

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1-2026, argenx reported an EPS of $5.52, surpassing estimates by 6.94%. However, the stock price fell by 2.51% the following day, indicating mixed market reactions.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to expanding the pipeline of therapies.
Plans to enhance partnerships with other biotech firms.

Expectations

Wall Street Expectations

Overall, expectations for argenx are cautiously optimistic, given their consistent EPS surprises in the past. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If argenx continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

On the other hand, if the company fails to provide clear revenue guidance or if the EPS falls short of expectations, it could lead to a significant sell-off.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.52.

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

Market Reaction

N/A

Understanding how the stock reacts post-earnings can provide insights into investor sentiment and future expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this number will be critical in shaping investor sentiment.

Will there be any guidance on revenue growth?

Lack of revenue guidance has historically led to uncertainty, and any clarity on this front could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate argenx's ability to maintain its EPS surprise streak, given the strong pipeline and recent advancements.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a larger move than historical averages, indicating heightened expectations.

Recent clinical trial results may not yet be fully factored into current estimates.

Key Risk

If the EPS comes in below $5.30, it could challenge the current positive sentiment and lead to a reevaluation of growth prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching the EPS and any revenue guidance, as these will be key indicators of the company's ongoing performance and future outlook.

Bull Confirmed If

An EPS of $5.75 or higher would confirm strong operational performance and likely boost investor confidence.

Bear Confirmed If

An EPS below $5.30 would raise concerns about the company's growth trajectory and could lead to a sell-off.

Pre-Earnings Positioning

Options Market

Implied Move

±14.75%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations and raises guidance, history suggests the stock could rise by around 0.79% on the following day.

In-Line / Cautious

If results are in line with expectations but lack clear guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 5.01% on the next trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial progress and outcomes.
2Management's commentary on revenue expectations and market conditions.
3Insights into partnerships or collaborations that may impact growth.
4Details on cost management and operational efficiencies.
5Future pipeline developments and their expected timelines.